re: News: Biotron's Hep C drug candidate phas...
Very, very exciting prospect here IMO (for the hearing impaired)
Dr.Michelle Miller CEO
"regulatory authorities such as the FDA in the US have been really clear in saying they are very keen to see trials quickly, and development through the market quickly, in difficult to treat hepatitis C populations and one of those groups is the HIV and HCV co-infected populations. Up to 30% of HIV patients are also are also infected with Hep C".
"Biotron is in the unique position of having this drug BIT-225 which has activity against both HIV and Hepatitis C".
Bring on the deal/s !!!
Cheers, FF
BIT Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)